Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 127

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.07 Daily Weekly Monthly
20 Day Moving Average: 808,139 shares
Shares Outstanding: 74.77 (millions)
Market Capitalization: $1,500.61 (millions)
Beta: 0.47
52 Week High: $22.76
52 Week Low: $16.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.15% -8.46%
12 Week 8.08% 5.36%
Year To Date 15.68% 0.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 innoviva@argotpartners.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo, Esq. - Chairman
Stephen Basso - Chief Financial Officer
Odysseas Kostas - Director
Jules Haimovitz - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 74.77
Most Recent Split Date: (:1)
Beta: 0.47
Market Capitalization: $1,500.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.04 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.84
Trailing 12 Months: 7.52
PEG Ratio: -
Price Ratios
Price/Book: 1.49
Price/Cash Flow: 5.86
Price / Sales: 3.86
EPS Growth
vs. Year Ago Period: 5,300.00%
vs. Previous Quarter: 40.26%
Sales Growth
vs. Year Ago Period: 20.44%
vs. Previous Quarter: 7.50%
ROE
09/30/25 - 28.17
06/30/25 - 18.67
03/31/25 - 15.77
ROA
09/30/25 - 16.23
06/30/25 - 9.92
03/31/25 - 8.41
Current Ratio
09/30/25 - 14.12
06/30/25 - 2.64
03/31/25 - 2.48
Quick Ratio
09/30/25 - 13.33
06/30/25 - 2.44
03/31/25 - 2.30
Operating Margin
09/30/25 - 55.53
06/30/25 - 34.31
03/31/25 - 28.49
Net Margin
09/30/25 - 32.78
06/30/25 - 10.44
03/31/25 - -16.15
Pre-Tax Margin
09/30/25 - 40.29
06/30/25 - 17.71
03/31/25 - -12.53
Book Value
09/30/25 - 13.51
06/30/25 - 11.34
03/31/25 - 10.31
Inventory Turnover
09/30/25 - 1.29
06/30/25 - 0.93
03/31/25 - 0.94
Debt-to-Equity
09/30/25 - 0.25
06/30/25 - 0.36
03/31/25 - 0.40
Debt-to-Capital
09/30/25 - 20.31
06/30/25 - 26.45
03/31/25 - 28.41
 

Powered by Zacks Investment Research ©